
Moderna Inc
NASDAQ:MRNA

Intrinsic Value
The intrinsic value of one
MRNA
stock under the Base Case scenario is
33.51
USD.
Compared to the current market price of 25.13 USD,
Moderna Inc
is
Undervalued by 25%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Moderna Inc
Fundamental Analysis

Moderna’s revenue remains heavily reliant on its COVID-19 vaccine, and diminished global demand for boosters, along with heightened competition from alternative formulations, could significantly erode sales and margins.
The mRNA platform’s modular nature and rapid development cycle positions Moderna to quickly expand its pipeline beyond COVID-19, enabling potential breakthroughs in vaccines for influenza, RSV, cancer, and rare diseases.

Revenue & Expenses Breakdown
Moderna Inc
Balance Sheet Decomposition
Moderna Inc
Current Assets | 8.1B |
Cash & Short-Term Investments | 7B |
Receivables | 592m |
Other Current Assets | 482m |
Non-Current Assets | 6B |
Long-Term Investments | 2.5B |
PP&E | 3B |
Intangibles | 92m |
Other Non-Current Assets | 488m |
Free Cash Flow Analysis
Moderna Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Moderna Inc
Revenue
|
3.2B
USD
|
Cost of Revenue
|
-969m
USD
|
Gross Profit
|
2.3B
USD
|
Operating Expenses
|
-5.7B
USD
|
Operating Income
|
-3.5B
USD
|
Other Expenses
|
-111m
USD
|
Net Income
|
-3.6B
USD
|
MRNA Profitability Score
Profitability Due Diligence
Moderna Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.

Score
Moderna Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
MRNA Solvency Score
Solvency Due Diligence
Moderna Inc's solvency score is 68/100. The higher the solvency score, the more solvent the company is.

Score
Moderna Inc's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MRNA Price Targets Summary
Moderna Inc
According to Wall Street analysts, the average 1-year price target for
MRNA
is 53.14 USD
with a low forecast of 25.25 USD and a high forecast of 222.6 USD.
Dividends
Current shareholder yield for MRNA is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
MRNA
stock under the Base Case scenario is
33.51
USD.
Compared to the current market price of 25.13 USD,
Moderna Inc
is
Undervalued by 25%.